DUBLIN, Nov. 19, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/cstdbn/immunotherapeutic) has announced the addition of the "Immunotherapeutic Global Market - Forecast To 2021" report to their offering.
The immunotherapeutics global market is expected to grow at mid range CAGR to reach $138.9 billion by 2021
The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs.
The field of immunotherapy has been successful in attracting some of the biggest pharmaceutical & Biotech companies. These players are forging alliances with several small biotech's and academic institutes to discover new and more effective ways of exploiting the power of the body's own immune system in fighting tumors. As a result, the ImmunoOncology battle is getting intensified day-by-day.
Large Pharmaceutical/Biotech companies like Roche, AbbVie, J&J, Biogen and Amgen are ahead of other companies with their marketed compounds and strong pipelines and are considered as leaders in this space. Similarly, Celgene, BMS and Merck & Co. are leading in checkpoint inhibitor market. While, companies like Astrazeneca, GlaxoSmithKline and Eli Lilly are not as much active as these, but they are not far behind as they can choose the inorganic way to beef-up their pipelines and the current deal strategy shows a similar trend.
Small and mid-size biotech firms could benefit from this race of large pharma/biotechs via asset acquisition, research collaboration or Co-development. Some of these late entrant's are trying to work on next-generation immuno-oncology approaches, as they were not competitive with first-generation drugs like PD1 checkpoint inhibitors.
Key Topics Covered:
1 Executive Summary
3 Market Analysis
4 Immunotherapeutics Global Market, By Type
5 Immunotherapeutics Global Market, By Application
6 Regional Market Analysis
7 Company Developments
8 Major Player Profiles
- Abbvie, Inc. - Amgen, Inc. - Biogen - Bristol-Myers Squibb - Celgene - Johnson & Johnson - Merck & Co, Inc. - Novartis Ag - Pfizer, Inc. - Roche
For more information visit http://www.researchandmarkets.com/research/cstdbn/immunotherapeutic
Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets